Top Markets
#1 Status Status +12.47%
#2 TENDIES TENDIES +7.93%
#3 Ontology Gas Ontology Gas +7.80%
#4 StonkBroker StonkBroker +7.11%
#5 Wrapped Flare Wrapped Flare +4.36%
#6 Tutorial Tutorial +3.31%
#7 Nano Nano +3.23%
#8 Atoshi Atoshi +2.82%
#9 SPX6900 SPX6900 +2.71%
#10 Gas Gas +2.33%
Coin of the day
Status Status
Settings
Language
ENGLISH
Currency
USD
Theme
LB Pharmaceuticals Inc Common Stock LB Pharmaceuticals Inc Common Stock

LB Pharmaceuticals Inc Common Stock

LBRX
Rank in Stocks #8002
This biopharmaceutical firm is currently in the clinical development stage,... This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Share Price
$48.45
Market Cap
$1.39B
Change (1 day)
1.16%
Change (1 year)
-
Country
US
Trade LB Pharmaceuticals Inc Common Stock (LBRX)

Category

Healthcare
Revenue for LB Pharmaceuticals Inc Common Stock (LBRX)
Revenue in Aug 2026 TTM: 0
According to LB Pharmaceuticals Inc Common Stock latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for LB Pharmaceuticals Inc Common Stock from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH